{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:44:41Z","timestamp":1787013881901,"version":"build-2736575974"},"reference-count":98,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T00:00:00Z","timestamp":1434326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The discontinuation of anti\u2010tumour necrosis factor (anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      ) treatment in inflammatory bowel disease (\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      ) patients in remission could be considered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To evaluate the factors associated with relapse of\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      after discontinuation of anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Electronic (PubMed\/Embase) and manual search up to January 2015.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall risk of relapse after discontinuation of anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      s (27 studies) was 44% for Crohn's disease (CD; follow\u2010up range: 6\u2013125\u00a0months) and 38% for ulcerative colitis (follow\u2010up range: 6\u201324\u00a0months). Several factors were investigated to identify patients who are more likely to achieve long\u2010lasting remission after anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      discontinuation. The factors associated with a higher risk of relapse are younger age, smoking, longer disease duration, and fistulising perianal CD. Laboratory markers such as low haemoglobin levels, high C\u2010reactive protein levels and high faecal calprotectin seem to increase the risk of relapse. On the other hand, low serum anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      levels seem to be associated with a lower risk of flare\u2010up. Mucosal healing seems to decrease the risk of relapse after anti\u2010TNF discontinuation (overall, this risk is 26% at 1 year with mucosal healing and 42% without), although this observation has not been confirmed by some authors. In patients receiving escalated anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      doses or receiving anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      s for the prevention of post\u2010operative CD recurrence, the risk of relapse after discontinuation is high (&gt;75%). Re\u2010administration of the drug in those who relapsed after stopping treatment is effective and safe.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A high proportion of patients with\n                      <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>\n                      relapse after discontinuation of anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      treatment. As available data are insufficient to make strong recommendations on when anti\u2010\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      therapy could be stopped, decisions should be taken on an individual basis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.13276","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T06:27:03Z","timestamp":1434349623000},"page":"391-405","source":"Crossref","is-referenced-by-count":108,"title":["Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti\u2010\n                    <scp>TNF<\/scp>\n                    therapy"],"prefix":"10.1111","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"J. P.","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit Hospital Universitario de La Princesa and Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS\u2010IP) Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Mar\u00edn","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Hospital Universitario de La Princesa and Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS\u2010IP) Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit Hospital Universitario de La Princesa and Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS\u2010IP) Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,15]]},"reference":[{"key":"e_1_2_22_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"e_1_2_22_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.203"},{"key":"e_1_2_22_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20927"},{"key":"e_1_2_22_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.056"},{"key":"e_1_2_22_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.048"},{"key":"e_1_2_22_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.138"},{"key":"e_1_2_22_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.006"},{"key":"e_1_2_22_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21792"},{"key":"e_1_2_22_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03709.x"},{"key":"e_1_2_22_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.660541"},{"key":"e_1_2_22_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945010790309957"},{"key":"e_1_2_22_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju027.590"},{"key":"e_1_2_22_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.12.035"},{"key":"e_1_2_22_15_1","unstructured":"Bortl\u00edkM Duricov\u00e1D Luk\u00e1\u0161M et\u00a0al.Infliximab trough levels at treatment discontinuation are associated with increased risk of disease relapse in patients with inflammatory bowel diseases. 20th United European Gastroenterology Week2012: P0870."},{"key":"e_1_2_22_16_1","article-title":"Outcome of elective withdrawal of anti\u2010tumour necrosis factor\u2010alpha therapy in patients with Crohn's disease in established remission","author":"Brooks AJ","year":"2015","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-008-0411-0"},{"key":"e_1_2_22_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02670.x"},{"key":"e_1_2_22_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31815604cd"},{"key":"e_1_2_22_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2013-100392"},{"key":"e_1_2_22_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.09.034"},{"key":"e_1_2_22_22_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i36.5058"},{"key":"e_1_2_22_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12160"},{"key":"e_1_2_22_24_1","first-page":"1021","article-title":"Outcome after discontinuation of TNFalpha\u2010blocking therapy in patients with inflammatory bowel disease in deep remission","volume":"20","author":"Molander P","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_22_25_1","unstructured":"EcharriA OlleroV GallegoC PortaA CastroJ.Anti\u2010TNF withdrawal in IBD patients on deep remission. Risk factors of relapse. 20th United European Gastroenterology Week 2012: P0287."},{"key":"e_1_2_22_26_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i39.5238"},{"issue":"1","key":"e_1_2_22_27_1","first-page":"P487","article-title":"Factors influencing recurrence following suspension of biological treatment. Importance of mucosal healing","volume":"8","author":"Ciria V","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.04.012"},{"issue":"1","key":"e_1_2_22_29_1","first-page":"P398","article-title":"Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5\u00a0years from a tertiary referral center","volume":"8","author":"Ramos L","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(13)60278-9"},{"issue":"1","key":"e_1_2_22_31_1","first-page":"P401","article-title":"Outcome of infliximab discontinuation in IBD patients and therapy rechallenging in relapsers: single centre preliminary data","volume":"8","author":"Marino M","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21615"},{"issue":"1","key":"e_1_2_22_33_1","first-page":"P402","article-title":"Normalized wall thickness at MRE predicts clinical remission in Crohn's disease after infliximab discontinuation: a 5\u00a0years follow\u2010up","volume":"8","author":"Annunziata ML","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04446.x"},{"key":"e_1_2_22_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(10)60555-5"},{"key":"e_1_2_22_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2013.845906"},{"key":"e_1_2_22_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(10)63179-4"},{"issue":"1","key":"e_1_2_22_38_1","first-page":"P405","article-title":"Mucosal healing in patients with ulcerative colitis treated with infliximab. What happens after treatment is discontinued?","volume":"8","author":"Mu\u00f1oz C","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110797"},{"key":"e_1_2_22_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.11.026"},{"key":"e_1_2_22_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12838"},{"key":"e_1_2_22_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20712"},{"key":"e_1_2_22_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"key":"e_1_2_22_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0089-1"},{"key":"e_1_2_22_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121491"},{"key":"e_1_2_22_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000442680.47427.bf"},{"key":"e_1_2_22_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.09.002"},{"key":"e_1_2_22_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0225-3"},{"key":"e_1_2_22_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12115"},{"key":"e_1_2_22_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12440"},{"key":"e_1_2_22_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.02.002"},{"key":"e_1_2_22_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"e_1_2_22_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.10.022"},{"key":"e_1_2_22_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000169"},{"key":"e_1_2_22_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2008.07.003"},{"key":"e_1_2_22_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.03.033"},{"key":"e_1_2_22_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.02.018"},{"key":"e_1_2_22_58_1","first-page":"117","article-title":"Role of biological markers in inflammatory bowel disease","volume":"30","author":"Gisbert JP","year":"2007","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_22_59_1","doi-asserted-by":"crossref","first-page":"P274","DOI":"10.1016\/S1873-9946(12)60294-3","article-title":"Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub\u2010analysis of the STORI study","volume":"6","author":"Suray N","year":"2012","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2008.05.008"},{"key":"e_1_2_22_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303957"},{"key":"e_1_2_22_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22861"},{"key":"e_1_2_22_63_1","first-page":"33","article-title":"Does fecal calprotectin predict short\u2010term relapse after stopping tnfalpha\u2010blocking agents in inflammatory bowel disease patients in deep remission?","volume":"9","author":"Molander P","year":"2015","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_64_1","first-page":"978","article-title":"Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease","volume":"20","author":"Rajca S","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_22_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05057.x"},{"key":"e_1_2_22_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666141106104209"},{"key":"e_1_2_22_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.06.002"},{"key":"e_1_2_22_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.12.016"},{"key":"e_1_2_22_69_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2995"},{"key":"e_1_2_22_70_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.758773"},{"key":"e_1_2_22_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_22_72_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_22_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.88"},{"key":"e_1_2_22_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04612.x"},{"key":"e_1_2_22_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04679.x"},{"key":"e_1_2_22_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.03.018"},{"key":"e_1_2_22_77_1","first-page":"A255","article-title":"Dose de\u2010escalation in patients with inflammatory bowel disease treated long\u2010term with adalimumab 40\u00a0mg weekly","volume":"57","author":"Karmiris K","year":"2008","journal-title":"Gut"},{"key":"e_1_2_22_78_1","first-page":"S103","article-title":"Effectiveness of a dose \u201cde\u2010escalation\u201d strategy with anti\u2010TNF drugs in patients with Crohn's disease","volume":"5","author":"Chaparro M","year":"2011","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(13)60413-4"},{"key":"e_1_2_22_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.6.665"},{"key":"e_1_2_22_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20909"},{"key":"e_1_2_22_82_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.051"},{"key":"e_1_2_22_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.016"},{"key":"e_1_2_22_84_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353374"},{"key":"e_1_2_22_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.171"},{"key":"e_1_2_22_86_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920111795470903"},{"key":"e_1_2_22_87_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.959489"},{"key":"e_1_2_22_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.024"},{"issue":"1","key":"e_1_2_22_89_1","first-page":"340","article-title":"Anti\u2010TNF is safe to stop in the second trimester of pregnancy in IBD women in remission","volume":"146","author":"Lima A","year":"2014","journal-title":"Gastroenterology"},{"key":"e_1_2_22_90_1","first-page":"B4652","article-title":"Biologic therapy in inflammatory bowel disease","volume":"60","author":"Theede K","year":"2013","journal-title":"Dan Med J"},{"key":"e_1_2_22_91_1","unstructured":"Anon.NICE Technology Appraisal Guidance 187: infliximab (review) and adalimumab for the treatment of Crohn's disease. National Institute for Health and Clinical Excellence 2010. Available at:http:\/\/guidance.nice.org.uk\/TA187."},{"key":"e_1_2_22_92_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.12-3-235"},{"key":"e_1_2_22_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.392"},{"key":"e_1_2_22_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.013"},{"key":"e_1_2_22_95_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"issue":"1","key":"e_1_2_22_96_1","first-page":"P363","article-title":"Retreatment with infliximab in inflammatory bowel disease: tolerability and effectiveness of different re\u2010induction regimens","volume":"8","author":"Felice C","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_22_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281f4c4"},{"key":"e_1_2_22_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.01.033"},{"key":"e_1_2_22_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181962dfa"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13276","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:39:50Z","timestamp":1695490790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,15]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/apt.13276"],"URL":"https:\/\/doi.org\/10.1111\/apt.13276","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,15]]}}}